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Pyridine ruthenium (III) complexes
PC-3 prostate cancer cells
A B S T R A C T
The ﬁrst aim of the present study is the development of a new ruthenium(III) complex, belonging to NAMI-A
class, with a potentially high cytotoxic ability. The presence of a fully protected sugar moiety as ruthenium
ligand should increase the complex ability to cross cellular membranes. Furthermore, it sets this molecule in the
area of biocompatible agents as tumor drug. The second, more relevant, purpose is to verify the ruthenium
complexes activity after loading into liposomes. We reported the characterization and in vitro biological assays
of pyridine derivatives of ruthenium complexes loaded into Egg L-α-phosphatidylcholine cholesterol/DSPE-PEG
liposomes. Dynamic light scattering estimates that the sizes of all obtained liposomes are in the 100 nm range.
This value is suitable for in vivo use. The loading ability and release kinetic allowed selecting the best ratio
between the lipid fraction and metal to be tested in cellular experiments. The growth inhibitory eﬀects of both
liposomal and free complex in PC-3 prostate cancer cell lines demonstrate a high cytotoxic ability of the lipo-
some entrapped ruthenium (III) complex suggesting additional role further the antimetastatic function.
1. Introduction
Metal-based anticancer drugs fulﬁll an important role in the ﬁght
against cancer pathologies. The ﬁrst metal complex approved for clin-
ical use by FDA was Cisplatin (CDDP) in 1978 [1]. Since then, platinum
based drugs are pivotal drugs for treatment of many human tumours
like testicular and ovarian cancers and nowadays Cisplatin is one of the
three top-selling chemotherapeutic drugs. However, the che-
miotherapic use of platinum complexes is strongly limited by many and
severe side eﬀects and acquired tumor resistance [2–5]. These limits
pushed researchers and pharma companies to develop other complexes
of transition metals [6,7]. Among them, a prominent role is occupied by
ruthenium complexes in the oxidation states II and III [8–11]. In prin-
ciple, these compounds oﬀer several advantages: ﬁrst of all some Ru
(III)-based derivatives act against cancer cells that were resistant to
platinum compounds following a diﬀerent mechanism of action [12].
The research was focused on two complexes: imidazolium [trans-
RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) [13,14] and indazolium
[trans-RuCl4(1H-indazole)2] (KP1019) [15]. NAMI-A was validated
against lung metastases of a number of solid metastasizing tumours,
including a NSCLC of human origin engrafted in the nude mouse
[16–19], but it does not show cytotoxic activity in the 60-cell-line NCI
panel for in vitro anticancer drug screening [20]. On the other hand
KP1019 acts as cytotoxic drug, eﬀective against primary tumours as
colorectal tumours [21], and recently it has been shown that it also
likely act as an antimetastatic agent [22]. Both complexes overcame the
early stage in clinical trials [13,15].
The promising properties of ruthenium complexes can be attributed
to ligands exchange in biological media. NMR studies carried out in the
last decades provided evidence that the coordination of Ru is deeply
transformed in physiological conditions: NAMI-A undergoes both
chloride and DMSO hydrolysis while forming a mixture of hydrolyzed
species in about 15min [23]. This is the ﬁrst step in protein binding of
all ruthenium complexes. Indeed, in most of experiments carried out
(e.g. serum albumin adducts formation [24]) it was observed the loss of
original ligands coordinated to the metal center [25,26].
All results seem to agree that NAMI-A acts like a pro-drug, even if
the integrity of ruthenium complexes is essential to store the cytotoxic
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activity because its metabolites interact mainly with cell membrane and
are not signiﬁcantly internalized by cells [27,28]. In contrast, the pre-
sence in both cytosol and in the nuclear region of ruthenium centers
generated by KP1019 was demonstrated by X-ray ﬂuorescence imaging.
This occurrence increases cytotoxic activity, compared to NAMI-A [29].
The detected outcome is due to slower extracellular degradation al-
lowing enhanced cellular uptake through passive diﬀusion.
In this scenario the condition of administration of ruthenium drugs
seems crucial to exploit their anticancer activity. Indeed, in the last
years innovative strategies have been developed to vehicle ruthenium
ions in tumor cells. They could be summarized in three main oppor-
tunities. First, ruthenium centers can be coordinated by bioactive li-
gands or by ligands bearing a bioactive molecule able to drive the entire
complex toward tumor cells [30,31]; the second opportunity is that
ruthenium complexes are endowed with a chemical moiety able to
polymerize or to promote formation of supramolecular aggregates
[32–34]; and the last possibility is that in which ruthenium complexes
can be physical encapsulated in nanoparticles [35]. In the ﬁrst two
strategies the cytotoxic activity of ruthenium drugs enhances compared
with NAMI-A but in both cases deep modiﬁcations are required on li-
gand structures. Although introduction of new moieties did not aﬀect in
most of the case the electronic properties and the rate of ligand ex-
changes in physiological conditions, increasing the drug eﬃcacy, the
protocol to begin a clinical evaluation requires more heavy procedures.
The third strategy allows to preserve the same drug structure and to
increase stability in aqueous solutions. Moreover, like the second ap-
proach, the nanoparticle formulation facilitated cellular accumulation.
Therefore loading in nanoparticles was pursued for Cisplatin by in-
creasing the cytotoxic eﬀects and reducing resistance phenomena [36].
Currently, a liposomal formulation based on 1,2-dipalmitoylpho-
sphatidylglycerol (DPPG) (Lipoplatin™ traded by Regulon Inc, Moun-
tainView, CA) [37] reaches the latter phase in clinical trials. Despite
these positive results to the best of our knowledge only KP1019 was
entrapped in Poly(lactic acid) nanoparticles with Pluronic F68 and
Tween 80 surfactants. This formulation shows enhanced cytotoxic ac-
tivity [33].
Our study aims to incorporate ruthenium complexes in the inner
aqueous compartment of liposomes and to test biological properties of
two NAMI-A like pyridine derivatives. Recently Walsby's group syn-
thesized NAMI-A analogues modifying the axial pyridine ligand that is
pivotal for the features of the ruthenium complexes, demonstrating that
the growth of lipophilicity enhances in vitro cytotoxicity [38–40]. In-
spired by these evidences speciﬁcally, in this work we have explored
two pyridine derivatives of the sodium-compensated analogue of NAMI-
A, Na[trans-RuCl4(pyridine)(DMSO)] (RuPy) and Na[trans-
RuCl4(PyTry)(DMSO)] (RuPyTry) (Fig. 1). In the latter complex the
pyridine ligand is functionalized with a fully protected sugar moiety to
increase biocompatibility and the ability to cross the cell membrane due
the lipophilic moiety. Additionally, carbohydrates allow to provide
multiple points of interaction as H-bond donor or acceptor, tuning the
hydrophilic properties [41,42].
The liposome was formulated mixing Phosphatidylcholine (PC)/
Cholesterol (Chol)/DSPEPeg2000 in molar ratio 57/38/5. This com-
position was selected reproducing similar composition of other systems
already tested in clinical phases such as delivery systems [43].
Moreover, we have assessed the best concentration and the ability to
load both complexes. Lastly the cytotoxic properties were tested on PC-
3 tumor cells.
2. Materials and methods
Phosphatidylcholine and cholesterol (Chol) were purchased from
Avanti Polar Lipids (Alabaster, AL). All the other chemicals were
commercially provided by Sigma-Aldrich (Bucks, Switzerland) or
LabScan (Stillorgan, Dublin, Ireland) and were used as received unless
further puriﬁcation. [(DMSO)2H][trans-Ru(DMSO)2Cl4] [44], Na+
[trans-Ru(DMSO)2Cl4] [44], Na[Ru(Py)(DMSO)Cl4] (RuPy) [34] and
PyTry [45] were synthesized as previously described. All the aqueous
solutions were prepared by weight adding MilliQwater. The products
were characterized by 1HNMR spectroscopy. The spectra were recorded
with a Bruker AVANCE 400 spectrometer. FTIR spectra were acquired
by Jasco FT/IR 4100 (Easton, MD, USA). Liposomes were extruded
using a thermo barrel extruder system (Northern Lipids Inc, Vancouver,
BC, Canada). Inductively Coupled Plasma atomic emission Mass Spec-
troscopy (ICP-MS) (ICP SPECTRO Arcos with End On Plasma torch;
Spectro Analytical, Kleve, Germany) equipped with a capillary cross-
ﬂow nebulizer.
2.1. Synthetic procedures
2.1.1. Synthesis of Na[Ru(PyTry)(DMSO)Cl4] - (RuPyTry) complex
PyTry ligand (65mg, 0.118mmol) was added to a suspension of
freshly prepared [Na][trans-RuCl4(DMSO)2] (50mg, 0.118mmol) in
acetone (4mL). The mixture was stirred at 40 °C and the reaction was
monitored by TLC on alumina. After 4 h the solvent was removed under
reduced pressure, giving the desired salt in pure form (yield > 95%).
IR: 2915 cm−1, 2850 (DMSO) 1748 (C=O) 1632 (C=C) 1414 1235
MS: (CH3OH) 830m/z. (M+1) MS (H2O) 819m/z (M-
2Cl− + 2H2O + Na+), 797m/z (M-2Cl− + 2H2O + H+).
2.1.2. Ruthenium complexes stability
RuPy and RuPyTry complexes were separately dissolved in glass
vials in 1.0 mL phosphate buﬀer solution at pH 7.3 giving molar con-
centrations of 2.5 · 10−3 M. The solutions were monitored by UV–Vis
spectroscopy for 72 h after their preparation. The stability of these
complexes was also evaluated in similarly prepared aqueous solution.
2.2. Liposomes preparation and ruthenium complexes loading
Empty aggregates composed of PC/Chol/DSPEPeg2000 in molar
ratio 57/38/5 were formulated by the thin ﬁlm hydration method. The
three molecules were dissolved in MeOH/CHCl3(50/50 v/v) solution
and mixed in appropriate amounts. A thin ﬁlm was obtained by eva-
porating the organic solvents by slowly rotating the vial containing the
solution under a stream of nitrogen. Lipid ﬁlms were then hydrated in
saline solution containing 0.9% w/w of NaCl, sonicated for 30min and
extruded 10 times at room temperature through a polycarbonate
membrane with 100 nm pore size, using a thermo-barrel extruder
system under N2. The RuPy and RuPyTry loaded liposome were pre-
pared following the same procedure adding to organic mixture the
ruthenium compound dissolved in methanol. Unencapsulated ruthe-
nium complexes were removed by loading the supernatant on pre-
equilibrated Sephadex G50 column. Liposomal fractions were collected
and analyzed. The drug loading coeﬃcient (DL%, deﬁned as the weight
percentage between the loaded ruthenium complexes and the amphi-
philic liposome components), the encapsulation ratio (ER%, deﬁned as
the weight percentage of ruthenium complex encapsulated in the li-
posome on the total complex previously added) and the metal contents
Fig. 1. Chemical structure of the ruthenium complexes RuPy (left) and RuPyTry
(right).
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were quantiﬁed by means of ICP-MS.
2.3. Ruthenium complexes release
1mL of liposomes loaded with Ru complexes, were formulated at
5mM concentration as described above and introduced into a dialysis
bag (MW cut-oﬀ=3500 Da). The bag was placed into 20mL of fetal
bovine serum and incubated under stirring for 72 h at 37 °C. 2.5mL of
the dialyzed serum solution were replaced with an equivalent amount
of fresh serum at diﬀerent time points. The extent of ruthenium com-
plex release was evaluated by ICP-MS analysis as percentage of the ratio
between the amount of released metal and of the total metal previously
loaded into the liposomes.
2.4. Dynamic light scattering characterization
Dynamic light scattering (DLS) measurements were carried out
using a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA)
that employs a 173° backscatter detector.
Other instrumental settings are measurement position (mm): 4.65;
attenuator: 8; temperature 25 °C; cell: disposable sizing cuvette. Before
starting with DLS measurements, previously prepared samples were
diluted at ﬁnal concentration of 2.0 · 10−4 M and centrifuged at room
temperature at 13.000 rpm for 5min. For each formulation, RH and P.I.
were calculated as the mean of three measurements on three diﬀerent
batches.
2.5. Cell culture and viability assay
Human prostate cancer PC-3 cells were grown in RPMI 1640
medium (GIBCO, USA) supplemented with 10% fetal bovine serum
(GIBCO, USA), 1% L-glutammine (LONZA, Belgium). The normal
human dermal ﬁbroblasts (NHDF) were purchased from Lonza, seeded
on T-25 primary ﬂasks (Beckton Dickinson) and maintained in ﬁbro-
blast basal medium supplemented with 2% FBS, 1mg/mL hydro-
cortisone, 10 ng/mL human epidermal grow factor, 3 ng/mL rh ﬁbro-
blast growth factor b. Cells were cultured in a humidiﬁed 5% carbon
dioxide atmosphere at 37 °C and harvested at approximately 90%
conﬂuence. Reduction of cell viability was determined by crystal violet
assay. Brieﬂy, PC-3 cells (4× 104/mL) were seeded in 96-well ﬂat-
bottom microplates and incubated overnight to allow cell adhesion.
Subsequently, culture medium was removed and cells were treated with
diﬀerent concentrations of RuPy and RuPyTry encapsulated in lipo-
somes, and free compounds, in quadruplicate. The absorbance intensity
of cell treated with empty liposomes were used as negative control.
After 48 h culture medium was removed, cells were washed with
Phosphate-Buﬀered Saline (PBS), ﬁxed and stained with 0,1% (w/v)
crystal violet in 25% methanol (Sigma-Aldrich) for 30min at dark.
Then crystal violet was removed and cells were washed twice and let
dry. Finally, dye was solubilized by adding 10% (v/v) acetic acid and
the amount of dye taken up was quantiﬁed with a plate reader
(ThermoMultiscan FC) at 595 nm. All data were expressed as
mean ± SD.
3. Results and discussion
3.1. Ru complex synthesis
The 1,4-disubstituted-1,2,3-triazole (PyTry) containing a carbohy-
drate moiety was synthetized exploiting the well-assessed pathway
based on click chemistry methods [45]. The synthesis of the Ru(III)
complex was carried out adapting the procedure reported for the
synthesis of RuPy complex [34].
The ligand PyTry was coordinated to Ru(III) by displacing a DMSO
molecule from the Na[trans-Ru(DMSO)2Cl4], aﬀording RuPyTry com-
plex (Fig. 2). This ligand was preferred as compared to 2-
ethynylpyridine derivative in order to avoid that the ligand can chelate
the ruthenium ion aﬀording to another class of compounds. The com-
plex was isolated in almost quantitative yield and characterized
through ESI-MS, IR and 1HNMR spectroscopy.
The RuPyTry complex formation was conﬁrmed by ESI-MS in me-
thanol, while the mass spectrum in water display many signals with the
same isotopic pathway. All peaks are attributable to ruthenium com-
plexes obtained by chloride ligands replacement by water molecules
(see below).
The paramagnetic ruthenium(III) ion broadens the 1HNMR signals
of coordinated ligands, not allowing a standard assignment procedure
(The spectrum is reported in supplementary materials). However, the
presence of two very broad signals at −1.80 and −12.5 ppm are di-
agnostic. The ﬁrst signal is attributed to coordinated pyridine ring and
the second is recognized for the methyl of the S-coordinated DMSO.
These attributions were assigned by comparison with related Ru
(III)−DMSO complexes in literature [10].
3.2. UV–Vis spectroscopic characterization
The hydrolysis of NAMI like Ru(III) complexes occurs by exchanging
chloride and DMSO ligands with water molecules. The formation of the
aqua complexes is considered essential as these species eﬀectively in-
teract with the in vivo targets [46]. The UV–Vis spectra allow to
monitor the reaction following the evolution over time of the chro-
mophores. The spectra were carried out in water and in saline phos-
phate buﬀer at diﬀerent pH and at 2.5mM concentration. The stability
of RuPy has been previously studied [47], while the spectra were car-
ried out again to compare its stability toward the hydrolysis of RuPyTry
at the same concentration (Fig. 3). The band centered at 395 nm is
attributed to the ligands to Ru charge transfer transition (Ru→ Cl CT).
For both complexes in saline buﬀer it gradually reduced in intensity
over time, more rapidly for RuPyTry disappearing for the latter com-
plex in ca. 1.30 h vs 5 h for RuPy. The simultaneous appearance of a
new band centered at 350 nm for both compounds was observed. It
reached the highest value at same time which that vanished the 395 nm
band. This ﬁrst step of hydrolysis is attributed to chloride ion sub-
stitution with a water molecule [46]. The easy formation of the
monoaqua complex of RuPyTry could be favored by the intramolecular
hydrogen-bonding properties of nitrogen atom in the triazole moiety of
PyTry ligand with the coordinated water molecule. Both mono-aqua
compounds evolved in complexes coordinated by a major number of
water molecules. This transformation involve the disappearance of the
350 nm centered band.
In aqueous acid solution, at pH < 6, both starting complexes are
more stable but if the spectrum of RuPy after 72 h is unaltered, RuPyTry
shows a more propensity to undergo hydrolysis.
3.3. Aggregates formulation and DLS characterization
Both anionic ruthenium complexes are clearly soluble in water de-
spite the lipophilic feature of the fully protected glucose moiety.
Therefore, the aqueous inner compartment of liposomes could host
Fig. 2. Synthesis scheme of the sugar bearing ligand complex (RuPyTry).
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RuPy and RuPyTry complexes. The surfactants used in liposome for-
mulation are selected to determine their structural properties (size,
charge, polydispersity index, in vivo stability, transition temperature)
and to inﬂuence the drug loading and release properties. On the basis of
these consideration the chosen phospholipid was PC (Egg L-a-phos-
phatidylcholine) which represents a good compromise between satu-
rated or unsaturated phospholipids. The unsaturated bonds increase
ﬂuidity and permeability with respect to HSPC used in other prepara-
tions and currently tested in clinical phase delivering metal complexes.
Moreover 38% of cholesterol, in order to increase membrane ri-
gidity, and 5% of DSPE-Peg (1,2-distearoyl-sn-glycero-3-phosphoetha-
nolamine) were added to the lipid composition. The presence of ﬂexible
PEG chains exposed on the liposome surface prevents liposome inter-
action with MPS macrophages, increasing the circulation time. All
formulations were prepared starting from a lipid ﬁlm, hydrating it with
0.9% w/w of NaCl by extensive bath sonication. The colloid solutions
were extruded at room temperature through a polycarbonate mem-
brane with 100 nm pore size to reduce liposome size. Unilamellar ve-
sicles were obtained. Loading of ruthenium complexes was achieved
into liposomes using the passive equilibration loading method. The
unloaded complex was removed eluting the supernatant on pre-equili-
brated SephadexG50 column. The drug loading contents (DL), mea-
sured with respect to the PC phospholipid content, and the encapsula-
tion eﬃciencies, are reported in Tables 1 and 2. Encapsulation
complexes amount was assessed by ICP-MS on the liposomal fraction.
Empty and loaded liposomes were characterized by DLS technique.
All data are listed in Table 1. Measurements were performed at a
concentration of 5∙10−4 molkg−1 in water solution. All aggregates
show a mono modal distribution indicating the presence of a single
population of aggregates. At inﬁnite dilution, RH value can be reason-
ably evaluated using the translational diﬀusion coeﬃcients in the Sto-
kes–Einstein equation [48]. The values are comparable to PC liposomes
previously reported when the 100 nm ﬁlters are used in the extrusion
process [49].
Variations of radius were observed for diﬀerent lipidic concentra-
tions or containing percentages of ruthenium complexes. The liposomes
dimension grows increasing the lipidic concentrations whereas the
amount of drug does not signiﬁcantly aﬀect the diameter of the ag-
gregates. Sizes of all obtained liposomes are suitable for in vivo use.
Indeed according to the EPR eﬀect, liposomes of size below 200 nm,
extravasate from the blood vessels into the tumor tissue driving the
payload [50]. Lipidic concentrations increase the polydispersity. This
trend appears to concern above all RuPyTry loaded liposomes (lipoR-
uPyTry) probably due to the higher DL% compared to lipoRuPy.
Nevertheless these values, a PDI of about 0.3, are considered to be
acceptable in drug delivery applications using lipid-based carriers [51].
Empty liposomes have an average value of a zeta potential of
−12.0mV with observing slight diﬀerence varying the molar phos-
pholipidic concentrations. These values are expected due to liposome
composition (57% mol of PC zwitterionic phospholipid and 5mol % of
DSPE-PEG2000 anionic phospholipid). Ruthenium compound loaded
liposomes showed the similar values. The presence of the complexes in
inner compartment does not signiﬁcantly alter the zeta potential.
3.4. Drug loading and release
Three diﬀerent phospholipid concentrations (2, 5 and 10mM) were
investigated. Moreover, diﬀerent ratios between the above reported
phospholipid concentration and the amount of the ruthenium com-
plexes were chosen (0.125, 0.250, 0.500 and 1.00mmol for 2mM,
0.500 and 1.00mmol for 5.0 and 10.0 mM). In Tables 1 and 2 are re-
ported DL% and ER %.
The loaded amount of RuPy complex is lower than that of RuPyTry
complex in all conditions. This outcome could be attribute to the pre-
sence of the fully protected sugar ligand. The hydrophobic feature of
this moiety probably allows stronger interactions within hydrophobic
region of the bilayers because of the van der Waals forces. The drug
loading coeﬃcient is more broadly inﬂuenced for both complexes by
two diﬀerent eﬀects, obviously by the initial amount of complexes and
the used lipid concentration, both of them providing an increase of the
DL percentage. In particular, for each lipid concentration, a progressive
increase of the drug encapsulated was observed for both complexes in
2mM lipid concentration going from 0.09 to 1.80 for RuPy and from
0.27 to 3.50 for RuPyTry. Moreover, decrease on the DL% was observed
by increasing the amount of lipid concentration from 2mM to 10mM,
respectively, thus maintaining a ﬁx ratio between the lipid concentra-
tion and the drug amount.
Hence, we can conclude that an increase of the lipid concentration
strength produces a more evident eﬀect on the loading properties of the
liposomes.
The release proﬁle of RuPy and RuPyTry from liposomes of both
complexes was followed within 72 h, using a dialysis membrane im-
mersed in fetal bovine serum at 37 °C.
We assumed that the crossing of ruthenium complexes through the
dialysis membrane happened very fast and that the overall release from
liposomes to the dialysis bag medium is the rate determining step. The
amount of ruthenium complexes released was estimated by ICP-MS
analysis. It is worth noting that very low percentages of complexes are
released in serum release (4%) and the main part of them released
within 30 h, for both complexes (Fig. 4). The slow release suggests a
high aﬃnity of the two ruthenium complexes toward the inner core of
liposome.
Fig. 3. UV–Vis absorption spectra of RuPy (top) and RuPyTry (bottom), both at
2.5 mM concentration in the saline phosphate buﬀer (pH 7.3), recorded at
diﬀerent times after dissolution in order to study the complexes stability vs
ligands exchange. The RuPyTry complex shows a more rapid evolution. In
aqueous acid solution at pH < 6both complexes, as expected, are more stable
(spectra not reported).
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3.5. Biological assays
The cytotoxicity of Ru compounds were measured on PC-3 cells and
the results are summarized in Fig. 5. Ru complexes as free drug 100 μM
did not show cytotoxic eﬀect. At further concentration of RuPy and
RuPyTry at 500 μM we found 30% and 15% reduction of cell viability
respectively. These results are comparable with literature data for RuPy
on diﬀerent cell model [34]. The liposomal formulation assessed after
48 h of treatments showed a signiﬁcant cytotoxic eﬀects. The highest
concentrations of lipoRuPy 3.2 μM and lipoRuPyTry 10 μM reduced the
viability of prostatic cells about at 80% and 60% respectively. In con-
trast free Ru used at a concentration about ten times higher than li-
posomal formulation were little cytotoxic. In addition, for comparison,
treatment with 8.0 μM of cisplatin induced a 50% reduction of cell
viability similar to lipoRuPyTry. Whereas lipoRuPy is more active at
lower concentrations, (data not reported in ﬁgure).
In addition, the eﬀect on cell viability of lipoRuPyTry was assessed
on NHDF cells to compare the results obtained on cancer cells.
As showed in Fig. 6 no eﬀect on cell viability was observed in the
normal cells. The diﬀerences between malignant cells versus normal
cells usually were found in studies of ruthenium complexes cytotoxicity
[52,53].
Literature data did not report the cytotoxic eﬀect of NAMI-A like
complexes on normal cells. Many diﬀerent causes can explain this be-
havior, but the reported assays at moment do not allow advancing
hypothesis.
4. Conclusions
The aim of this paper was to study chemical and biological behavior
of two NAMI-A class ruthenium complexes were studied. A new sugar-
incorporated Ru(III) complex was designed to increase biocompatibility
and the ability to cross the cell membrane. The complex was fully
characterized by 1H NMR and UV–Vis spectroscopy to identify the new
compound and to compare its ligand exchange properties in water to
RuPy. Therefore, both complexes were biologically investigated against
PC-3 prostate cancer cells. The cytotoxic properties of RuPyTry were
not enhanced when compared to RuPy. The presence of the fully sugar
protecting group should increase the ability to cross the cell membrane
due the lipophilicity of this moiety but the very fast exchange of
chlorido ligand with the water save the hydrophilic behavior of the
complex. According to literature data, this property induces a very low
cytotoxicity. In order to check if the delivery system inside the cell can
modify the biological eﬀect, both complexes were encapsulated in li-
posomes based on Egg PC and containing cholesterol and DPSE-PEG.
The latter components were added to PC to increase the rigidity of the
liposome wall and the blood circulation time. Structural data, loading
studies and stability measurements allow ensuring stability of these
systems. Liposomes ﬁt within a critical radii size range (60–80 nm), the
drug loading are comparable with classic formulations of metal drugs.
The biological results allow verifying a relevant cytotoxic ability of
Table 1
Structural parameters (hydrodynamic radius, PDI and zeta potential from dynamic light scattering measurements) for the diﬀerent RuPy loaded aggregates. The
encapsulation ratios (ER%) and the drug loading coeﬃcients (DL%) are also reported.
sample Lipid Concentration (mmol/L) RuPy (mmol) Added RH (nm) ± S.D. PDI Zeta potential (mV) DL% ER%
Lipo e 2 – 45.0 ± 10.6 0.114 −15.3 ± 4.92 – –
Lipo 1 2 0.125 10−3 55.0 ± 21.53 0.116 −14.3 ± 4.81 0.09 2.5
Lipo 2 2 0.250 10−3 62.2 ± 21.31 0.122 −12.3 ± 5.60 0.28 4.0
Lipo 3 2 0.500 10−3 60.4 ± 25.5 0.135 −13.4 ± 5.20 0.73 5.0
Lipo 4 2 1.00 10−3 80.2 ± 35.3 0.189 −11.3 ± 4.78 1.80 6.2
Lipo e 5 – 75.0 ± 10.6 0.316 −10.9 ± 4.51 – –
Lipo 5 5 0.500 10−3 79.2 ± 38 0.190 −10.9 ± 5.13 0.35 6.0
Lipo 6 5 1.00 10−3 80.4 ± 40 0.208 −11.7 ± 4.35 0.78 6.8
Lipo e 10 – 98.2 ± 45 0.283 –11.1 ± 4.49 – –
Lipo 7 10 0.500 10−3 84.3 ± 42 0.228 −11.9 ± 5.50 0.18 6.2
Lipo 8 10 1.00 10−3 63.3 ± 26 0.142 −12.9 ± 4.97 0.42 7.2
Table 2
Structural parameters (hydrodynamic radius, PDI and zeta potential from dynamic light scattering measurements) for the diﬀerent RuPyTry loaded aggregates. The
encapsulation ratios (ER%) and the drug loading coeﬃcients (DL%) are also reported.
SAMPLE Lipid concentration (mmol/L) RuPyTry (mmol) Added RH (nm) ± S.D. Zeta potential (mV) PDI DL%. ER%
Lipo A 2 0.125 10−3 75.7 ± 47.5 −12.5 ± 4.95 0.238 0.27 7.6
Lipo B 2 0.250 10−3 53.3 ± 18.67 −11.8 ± 5.05 0.089 0.70 10.0
Lipo C 2 0.500 10−3 76.9 ± 27.26 −12.3 ± 5.08 0.149 1.51 10.7
Lipo D 2 1.00 10−3 74.2 ± 20.16 −11.5 ± 4.65 0.052 3.54 13.0
Lipo E 5 0.500 10−3 76.5 ± 40.21 −11.9 ± 4.91 0.352 0.70 12.4
Lipo F 5 1.00 10−3 84.5 ± 42.19 −11.9 ± 5.40 0.182 2.10 19.0
Lipo G 10 0.500 10−3 80.3 ± 40.82 −11.2 ± 4.83 0.345 0.42 15.0
Lipo H 10 1.00 10−3 84.3 ± 40.64 −12.2 ± 5.23 0.311 1.64 29.3
Fig. 4. Release of RuPy and RuPyTry complexes. The amount of Ru complexes
released (%) was estimated by ICP.
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both Ru (III) complexes joining to the well demonstrated anti metastatic
properties. At the best of our knowledge this is the ﬁrst case in which a
ruthenium (III) complex shows cytotoxic ability higher than cisplatin.
Moreover, the lipoRuPyTry preparation is selective toward the malig-
nant cells.
The biological results could be explained making two hypothesis.
(1) The loading in the liposome allows that metal center acts inside the
cell overcoming the crossing membrane problem. (2) It can be suppose
that in the inner liposome compartment, the relative amount of water
makes slowest the ligand kinetic exchange. This occurrence preserves
longer the ruthenium pro-drug. Unfortunately, the low concentration of
the complexes does not allow following the ligand exchange by UV–Vis
spectroscopy. We can probably state that both eﬀects could be co-
operative and induce the observed behavior.
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